TWIST Bioscience Insider Emily Leproust Files Form 4
| Field | Detail |
|---|---|
| Company | Leproust Emily M. |
| Form Type | 4 |
| Filed Date | Mar 24, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-activity, form-4, ownership-change
TL;DR
**Twist Bioscience insider Emily Leproust filed a Form 4, signaling a change in her holdings.**
AI Summary
On March 20, 2026, Emily M. Leproust, a reporting person for Twist Bioscience Corp (TWST), filed a Form 4 indicating a change in beneficial ownership of securities. While the filing details the reporting person and the company, it does not specify the exact nature of the transaction (e.g., buy, sell, grant) or the number of shares involved. This matters to investors because Form 4 filings provide transparency into insider activity, which can signal management's confidence (or lack thereof) in the company's future prospects, potentially influencing stock price.
Why It Matters
This filing signals a change in an insider's holdings at Twist Bioscience, which can be an important indicator for investors tracking management sentiment and potential future stock performance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of insider activity and does not inherently indicate a high level of risk without further transaction details.
Analyst Insight
A smart investor would note this filing and then seek out the full transaction details within the Form 4 to understand if Emily M. Leproust bought or sold shares, and in what quantity, to gauge insider sentiment towards Twist Bioscience Corp.
Key Players & Entities
- Leproust Emily M. (person) — Reporting Person
- Twist Bioscience Corp (company) — Issuer
- 0001753655 (person) — CIK of Reporting Person
- 0001581280 (company) — CIK of Issuer
FAQ
Who is the reporting person in this Form 4 filing?
The reporting person in this Form 4 filing is Leproust Emily M., with CIK 0001753655.
Which company is the issuer associated with this Form 4 filing?
The issuer associated with this Form 4 filing is Twist Bioscience Corp, with CIK 0001581280.
What was the period of report for this Form 4 filing?
The period of report for this Form 4 filing was 2026-03-20.
When was this Form 4 filing accepted by the SEC?
This Form 4 filing was accepted by the SEC on 2026-03-24 at 16:05:10.
What is the SIC code for Twist Bioscience Corp?
The SIC code for Twist Bioscience Corp is 2836, which stands for Biological Products, (No Diagnostic Substances).
Filing Stats: 963 words · 4 min read · ~3 pages · Grade level 8.5 · Accepted 2026-03-24 16:05:10
Filing Documents
- marketforms-72713.html (4)
- marketforms-72713.xml (4) — 11KB
- 0001214659-26-003721.txt ( ) — 13KB
From the Filing
SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Leproust Emily M. (Last) (First) (Middle) C/O TWIST BIOSCIENCE CORPORATION 681 GATEWAY BLVD. (Street) SOUTH SAN FRANCISCO CALIFORNIA 94080 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol Twist Bioscience Corp [ TWST ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/20/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/20/2026 S 1,742 (1) D $ 43.7864 858,887 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (right to buy) $ 5.95 (2) 09/28/2025 Common Stock 0 0 D Employee Stock Option (right to buy) $ 8.82 (3) 09/28/2027 Common Stock 0 150,879 D Employee Stock Option (right to buy) $ 26.66 (4) 11/18/2028 Common Stock 0 266,539 D Employee Stock Option (right to buy) $ 23.33 (5) 10/23/2029 Common Stock 0 131,290 D Employee Stock Option (right to buy) $ 67.85 12/19/2022 08/31/2030 Common Stock 64,950 64,950 (6) D Explanation of Responses: 1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. 2. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 3. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 4. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 5. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each mont